Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study
Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study
We intended to identify the prognostic factors and the results of interventions on patients with liver metastatic midgut carcinoids. Five institutions that are part of United Kingdom and Ireland neuroendocrine tumour (NET) group took part in this study. Patients were included if they had histology proven NET of midgut origin and liver metastases at the time of the study. Clinical and biochemical data were collected retrospectively from hospital charts, pathology reports, radiology reports and biochemistry records for each patient. Three hundred and sixty patients were included in the study. The median survival from date of diagnosis was 7.69 years (confidence interval (CI) 6.40–8.99) and 5.95 years (CI 5.02–6.88) from date of diagnosis of liver metastases. On univariate analysis, increasing age at diagnosis, increasing urinary hydroxyindole acetic acid levels, increasing plasma chromogranin A levels, high Ki67, high tumour volume and treatment with chemotherapy were identified as factors associated with a significantly poorer outcome. Resection of liver metastases, resection of small bowel primary, treatment with somatostatin analogue therapy and treatment with peptide receptor therapy were associated with improved prognosis. Multivariate analysis revealed that age at diagnosis (P=0.014), Ki67 level (P=0.039) and resection of primary (P=0.015) were independent predictors of survival. This is the largest study to our knowledge looking specifically at the prognosis and clinical course of patients with liver metastatic midgut NETs. For the first time, we have shown that Ki67 and resection of primary are independent predictors of survival for this group of patients.
885-894
Ahmed, A.
29a81242-835e-4661-bffd-3831f02ee2b6
Turner, G.
9f7ce134-6989-4b42-ab86-6804f7721b42
King, B.
960f44b4-cc9c-4f77-b3c8-775530ac0061
Jones, L.
22c78e0c-734e-4268-8bfa-0aa585aa2ef0
Culliford, D.
25511573-74d3-422a-b0ee-dfe60f80df87
McCance, D.
f2e38207-c4e4-4b4d-b15f-b8020fb91096
Ardill, J.
a7c1ee23-6cfe-4d26-aec6-ad4f9d5d688c
Johnston, B.T.
12775360-f813-4707-b46f-e03e9b50c091
Poston, G.
60c39fcd-0b57-4e3c-94ee-e9c4ea3480ef
Rees, M.
7a007633-b3fa-4f43-981c-b851de36aea9
Buxton - Thomas, M.
c82388c9-d926-42a2-97c2-98011f898726
Caplin, M.
fcbea94e-454d-4070-96a2-39cb10ab785e
Ramage, J.K.
6b7b38f2-cee2-4e6c-bcba-313c7bafedc6
September 2009
Ahmed, A.
29a81242-835e-4661-bffd-3831f02ee2b6
Turner, G.
9f7ce134-6989-4b42-ab86-6804f7721b42
King, B.
960f44b4-cc9c-4f77-b3c8-775530ac0061
Jones, L.
22c78e0c-734e-4268-8bfa-0aa585aa2ef0
Culliford, D.
25511573-74d3-422a-b0ee-dfe60f80df87
McCance, D.
f2e38207-c4e4-4b4d-b15f-b8020fb91096
Ardill, J.
a7c1ee23-6cfe-4d26-aec6-ad4f9d5d688c
Johnston, B.T.
12775360-f813-4707-b46f-e03e9b50c091
Poston, G.
60c39fcd-0b57-4e3c-94ee-e9c4ea3480ef
Rees, M.
7a007633-b3fa-4f43-981c-b851de36aea9
Buxton - Thomas, M.
c82388c9-d926-42a2-97c2-98011f898726
Caplin, M.
fcbea94e-454d-4070-96a2-39cb10ab785e
Ramage, J.K.
6b7b38f2-cee2-4e6c-bcba-313c7bafedc6
Ahmed, A., Turner, G., King, B., Jones, L., Culliford, D., McCance, D., Ardill, J., Johnston, B.T., Poston, G., Rees, M., Buxton - Thomas, M., Caplin, M. and Ramage, J.K.
(2009)
Midgut neuroendocrine tumours with liver metastases: results of the UKINETS study.
Endocrine-Related Cancer, 16 (3), .
(doi:10.1677/ERC-09-0042).
(PMID:19458024)
Abstract
We intended to identify the prognostic factors and the results of interventions on patients with liver metastatic midgut carcinoids. Five institutions that are part of United Kingdom and Ireland neuroendocrine tumour (NET) group took part in this study. Patients were included if they had histology proven NET of midgut origin and liver metastases at the time of the study. Clinical and biochemical data were collected retrospectively from hospital charts, pathology reports, radiology reports and biochemistry records for each patient. Three hundred and sixty patients were included in the study. The median survival from date of diagnosis was 7.69 years (confidence interval (CI) 6.40–8.99) and 5.95 years (CI 5.02–6.88) from date of diagnosis of liver metastases. On univariate analysis, increasing age at diagnosis, increasing urinary hydroxyindole acetic acid levels, increasing plasma chromogranin A levels, high Ki67, high tumour volume and treatment with chemotherapy were identified as factors associated with a significantly poorer outcome. Resection of liver metastases, resection of small bowel primary, treatment with somatostatin analogue therapy and treatment with peptide receptor therapy were associated with improved prognosis. Multivariate analysis revealed that age at diagnosis (P=0.014), Ki67 level (P=0.039) and resection of primary (P=0.015) were independent predictors of survival. This is the largest study to our knowledge looking specifically at the prognosis and clinical course of patients with liver metastatic midgut NETs. For the first time, we have shown that Ki67 and resection of primary are independent predictors of survival for this group of patients.
This record has no associated files available for download.
More information
Published date: September 2009
Identifiers
Local EPrints ID: 143783
URI: http://eprints.soton.ac.uk/id/eprint/143783
ISSN: 1351-0088
PURE UUID: 57c43b53-1544-461c-8599-2ed98f3c5c51
Catalogue record
Date deposited: 13 Apr 2010 09:05
Last modified: 14 Mar 2024 02:49
Export record
Altmetrics
Contributors
Author:
A. Ahmed
Author:
G. Turner
Author:
B. King
Author:
L. Jones
Author:
D. Culliford
Author:
D. McCance
Author:
J. Ardill
Author:
B.T. Johnston
Author:
G. Poston
Author:
M. Rees
Author:
M. Buxton - Thomas
Author:
M. Caplin
Author:
J.K. Ramage
Download statistics
Downloads from ePrints over the past year. Other digital versions may also be available to download e.g. from the publisher's website.
View more statistics